SCHEMBL1372124

SCHEMBL1372124

CC(C)(C)OC(=O)N1C[C@H](C#N)C[C@H]1C(=O)Nc1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 3/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPC1 O15118 1/20 0.46
S1PR1 P21453 8/20 0.45
CYP2C9 P11712 6/20 0.45
S1PR2 O95136 1/20 0.43
CYP2D6 P10635 6/20 0.42
CYP3A4 P08684 4/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2C19 P33261 1/20 0.42
CFTR P13569 1/20 0.42
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
CFD P00746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1372122 1.00 HDAC8 (0.49) HDAC8MEN1KMT2ANPC1S1PR1
SCHEMBL1375465 0.86 CYP3A4 (0.57) HDAC8MEN1KMT2ANPC1S1PR1
SCHEMBL1375463 0.86 CYP3A4 (0.57) HDAC8MEN1KMT2ANPC1S1PR1
SCHEMBL1374798 0.78 S1PR1 (0.52) HDAC8MEN1KMT2ANPC1S1PR1
SCHEMBL1374795 0.78 S1PR1 (0.52) HDAC8MEN1KMT2ANPC1S1PR1
SCHEMBL7728024 0.77 MEN1 (0.62) HDAC8MEN1KMT2ANPC1CYP2C9
SCHEMBL7728781 0.77 MEN1 (0.62) HDAC8MEN1KMT2ANPC1CYP2C9
SCHEMBL7728020 0.77 MEN1 (0.62) HDAC8MEN1KMT2ANPC1CYP2C9
SCHEMBL30475244 0.76 CYP1A2 (0.46) HDAC8MEN1KMT2ANPC1CYP3A4
SCHEMBL7728565 0.76 MEN1 (0.51) HDAC8MEN1KMT2ANPC1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 HDAC8 1456/4885MEN1 2389/4885KMT2A 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.